In today’s briefing:
- MV Australia Equal Weight Index Rebalance: One Add & Capping Leads to A$290m Trade
- [Quiddity Index] MV Australia Equal Weight Dec 24 Rebal Results: Flow Expectations
- Inventurus Knowledge Solutions IPO: Superior Margins and Growth Warrants a Premium
MV Australia Equal Weight Index Rebalance: One Add & Capping Leads to A$290m Trade
- Telix Pharmaceuticals (TLX AU) is the sole (and somewhat surprising) inclusion for the VanEck Vectors Australian Equal Weight ETF (MVW AU) in December.
- The one inclusion, float changes and capping changes result in a one-way turnover of 5.5% leading to a round-trip trade of A$290m.
- Shorts have increased in Telix Pharmaceuticals (TLX AU) this year but there has been some covering in the stock recently.
[Quiddity Index] MV Australia Equal Weight Dec 24 Rebal Results: Flow Expectations
- The MV Australia Equal Weight Index represents the performance of large, liquid companies incorporated in Australia and listed on the ASX.
- Telix Pharmaceuticals (TLX AU) is an ADD for the December 2024 review, with no other changes to the index.
- We expect a one-way flow of $US90mm for December 2024, which translates to a turnover of 5.5%.
Inventurus Knowledge Solutions IPO: Superior Margins and Growth Warrants a Premium
- Inventurus Knowledge Solutions (IKSINCD IN) is looking to raise up to US$295m in its upcoming India IPO.
- It is a technology-enabled healthcare solutions provider, assisting physician enterprises in US, Canada and Australia, with a core focus in the US.
- We have looked at the company’s past performance in our earlier notes. In this note, we discuss the industry growth, conduct a quick peer comparison and discuss the company’s valuation.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
